Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T Nov 22 | 2022FDA Accepts Legend’s LB2102 (DLL-3 CAR-T) IND in SCLCAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Nov 15 | 2022Gracell to Submit GC012F’s IND for R/R MM in the US and China; GC012F Demonstrates 100% ORR in NDMM; Clinical Progress from GC007g, GC503, and GC506; Gracell’s Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, TCR Nov 14 | 2022ICT, Takeda, and PACT Pharma Report Clinical Data in Solid Tumors; SITC 2022 Final AnalysisAccess Free BlastFree
Posted in: Allogeneic, Autologous Nov 12 | 2022Fate Tx and Carisma Present Clinical Updates in Liquid and Solid Tumors; SITC 2022 Analysis 2Access Free BlastFree
Posted in: Allogeneic, CAR-T Nov 11 | 2022Poseida, CRISPR Tx, and Cellectis Present Novel Allogeneic CAR-T for Solid Tumors; SITC 2022 Analysis 1Access Free Blast
Free
Posted in: CAR-T, CD19 Nov 11 | 2022Breyanzi Absent from November’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T Nov 10 | 2022P-PSMA-101’s Clinical Enrollment Stopped; Multiple Program Updates Expected at ESMO I-O 2022; Poseida’s Q3 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR Nov 09 | 2022Afami-cel’s Rolling BLA Submission to Initiate in Q4 2022; Adaptimmune Prioritizes MAGE-A4 and PRAME Assets; No Major Updates for Gavo-cel and TC-510; Adaptimmune and TCR2 Tx Q3 2022 Earnings SummariesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Nov 09 | 2022KarMMa-2 Results to be Presented at ASH 2022; No Updates for bbT369 and SC-DARIC33; PBCAR269A Discontinued; 2seventy bio and Precision BioSciences Q3 2022 Earnings SummariesAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 07 | 2022Breyanzi Absent from November's CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD22, CS1 Nov 04 | 2022Updated Results from UCART123 and UCARTCS1 at ASH 2022; UCART20x22 and UCART22 Manufactured In-House; Cellectis’s Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Nov 04 | 2022New Yescarta Ph3 Trial (ZUMA-23) for 1L LBCL PostedAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Nov 04 | 2022Obe-cel’s BLA Filing Anticipated by YE 2023; Multiple Clinical Updates Expected at ASH 2022; Autolus’s Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Nov 03 | 2022Allogene Plans to Expand ALLO-501A’s Pivotal Trial to Europe; Clinical Updates Ahead of ASH 2022; New Manufacturing Facility in China; Allogene’s Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, TCR Nov 02 | 2022GSK Deprioritizes Cell Therapy Franchise; GSK’s Q3 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, CD19 Oct 28 | 2022Gilead Reports Increased Cell Therapy Revenue; Yescarta and Tecartus Approved in the EU; New Galapagos Asset Added to Gilead's Pipeline; Viral Vector Manufacturing Plant Receives FDA Approval; Gilead’s Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, TCR Oct 27 | 2022Thoughts on GSK’s Decision to Transfer Cell Therapy Programs to Adaptimmune and Terminate Collaboration with Lyell; Is GSK Giving Up on Cell Therapy?Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 26 | 2022Abecma’s Revenue Increases +20% QoQ Driven by ex-US Sales; KarMMa-2 Results to be Presented at ASH 2022; NEX-T Programs Deprioritized; BMS Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 25 | 2022Kymriah Sales Remain Flat Despite Japan Approval in ≥3L FL; Kymriah’s LCM Initiatives Deprioritized; YTB323’s Plans Under Review; Novartis Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: CAR-T, CD19 Oct 21 | 2022Thoughts on Kite’s Licensing Agreement with Refuge BiotechnologiesAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.